HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026. The call will also provide updates on key growth initiatives, including the company's limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The announcement highlights HeartBeam's progress in commercializing its proprietary 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company's platform is designed to be the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG, enabling portable cardiac monitoring outside medical facilities.
HeartBeam's technology aims to provide actionable heart intelligence, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. The company holds over 20 issued patents related to its technology. The conference call is expected to provide insight into the company's commercial traction and development milestones, which are critical for investors evaluating the company's growth trajectory.
For more details, the full press release is available at https://ibn.fm/yN939. Investors can also access the latest news and updates on the company via its newsroom at https://nnw.fm/BEAT.
The upcoming earnings call represents a key opportunity for stakeholders to assess the company's financial health and the progress of its strategic initiatives, particularly the limited commercial launch of its arrhythmia assessment system. Given the competitive landscape in cardiac monitoring, HeartBeam's ability to execute on its commercial strategy and advance its product pipeline will be closely watched.
